CPT in combination with thalidomide in refractory/relapsed MM.

Trial Profile

CPT in combination with thalidomide in refractory/relapsed MM.

Completed
Phase of Trial: Phase II

Latest Information Update: 09 Oct 2016

At a glance

  • Drugs Circularly permuted TRAIL (Primary) ; Thalidomide
  • Indications Multiple myeloma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 21 May 2012 Actual end date (28 Feb 2011) added as reported by Chinese Clinical Trial Register record.
    • 12 Apr 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top